Under the terms of the arrangement, Constellation will receive committed funding of $95 million, comprising an upfront payment and research funding for a three-year collaboration period. Constellation will be eligible for substantial development and commercialization milestone payments as well as up to double-digit royalties on commercial sales of multiple products by Genentech. Additionally, Constellation will retain exclusive development and commercialization rights to selected programs emerging from the collaboration, for which payments would be due to Genentech upon the successful commercialization of such products.

The parties will establish a research collaboration addressing multiple epigenetic target classes. Constellation will retain independent strategic direction, operational management and exclusive rights to programs outside of the collaboration scope, including its two most advanced programs that are focused on the development of inhibitors of the BET chromatin reader and EZH2 chromatin writer proteins.  Genentech has a future option to acquire all outstanding shares of Constellation based on pre-negotiated terms, which include a significant initial acquisition payment plus contingent value rights payments based on the future successful development and commercialization of multiple products by Genentech. Genentech’s option to acquire Constellation includes the BET and EZH2 programs as well as other programs outside the collaboration scope.

“Genentech is a global leader in the research and development of innovative medicines, and in combination with our class-leading product engine and deep expertise in chromatin biology will create a powerhouse dedicated to bringing the greatest benefit to patients from drugs that modulate epigenetic pathways,” said Mark A. Goldsmith, M.D., Ph.D., president and chief executive officer of Constellation Pharmaceuticals. “This is a groundbreaking partnership in terms of the structure, breadth and potential future clinical impact of products created through our complementary capabilities. The committed revenue and post-collaboration economics should  provide a highly attractive return for our investors.”

James Sabry, M.D., Ph.D., vice president of Genentech Partnering, added, “We believe Constellation is a leading company in chromatin biology and epigenetics drug discovery and an excellent partner for Genentech in this area. With scientists committed to the collaboration at both Constellation and Genentech working together in a highly integrated way, our goal is to discover and ultimately bring to market promising new therapies for patients with unmet medical needs in oncology, and potentially other therapeutic areas.”

 What is Epigenetics?

Drug development in the field of epigenetics is directed towards the identification of small molecules that inhibit the activities of proteins (epigenetic regulators) that add, remove or recognize various chemical modifications (or marks) to specific sites on DNA or chromosomal proteins.  These marks play a key role in determining whether a gene is on or off.  Epigenetic regulators are often referred to as writers (add modifications), erasers (remove modifications) and readers (bind to chromatin). Research at Constellation and by others has shown that abnormal epigenetic regulation contributes to many different diseases.

 In research into chromatin readers that appeared recently in the Proceedings of the National Academy of Sciences Constellation scientists demonstrated that transcription of the MYC oncogene can be suppressed using small molecule inhibitors of the BET family of chromatin adapters. MYC is a master regulator of diverse cellular functions and has long been considered a compelling therapeutic target because of its role in many human malignancies including hematologic and solid tumors. Also, continued research by Constellation on chromatin modifying enzymes has resulted in significant progress towards developing small molecule inhibitors of the histone lysine methyltransferase EZH2. This enzyme functions as part of a chromatin-associated protein complex implicated in the repression of gene expression. Recent cancer genomic sequencing studies have identified recurrent mutations in the EZH2 encoding genomic locus in a subset of human cancers. In addition numerous epidemiological data sets linking increased EZH2 expression to late stage disease with poor prognosis suggest a prominent role for EZH2 in human malignancies.

 About Constellation Pharmaceuticals

Constellation Pharmaceuticals leverages insights from the rapidly expanding field of epigenetics to discover and develop small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The company’s innovative product discovery engine targets both the enzymes that modify the dynamic structure of chromatin (writers and erasers) and other proteins that interact with chromatin (readers) to control gene expression. Restoration of normal gene expression through chromatin modulation by highly selective and specific inhibitors promises to be a powerful avenue for the development of important new medicines against a broad range of diseases. For more information, please visit the company's website at www.constellationpharma.com.

CAMBRIDGE, Mass. – September 26, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced the publication of a paper in the Proceedings of the National Academy of Sciences (PNAS) demonstrating that MYC transcription can be suppressed using small molecule inhibitors of the BET family of chromatin adaptors. MYC is a master regulator of diverse cellular functions and has long been considered a compelling therapeutic target because of its role in many human malignancies. The paper appears in the online early edition of PNAS the week of September 26, 2011.

The MYC gene is translocated in all patients with Burkitt’s lymphoma and in a significant number of patients with multiple myeloma or a form of lymphoma known as diffuse large B-cell lymphoma. It is also frequently amplified in solid tumors. Tumor dependence on MYC sometimes occurs as a result of mutations in upstream pathways that cause it to be aberrantly expressed. Suppression of MYC transcription through the inhibition of BET protein binding to chromatin represents a promising new therapeutic approach in oncology.

“While pharmacologic inhibition of MYC function has been widely sought, to date it has been challenging due to the diverse mechanisms that drive aberrant MYC expression and the overall difficulty of disrupting protein-protein interactions,” said Jim Audia, Ph.D., chief scientific officer of Constellation Pharmaceuticals. “This history makes the publication of our new findings particularly exciting. The tool compounds that we and others have used have been valuable in revealing the therapeutic opportunity for BET inhibition, but these compounds are not ideal for in vivo or clinical application. Constellation is now advancing rapidly toward the clinic with multiple product candidates optimized to realize the full potential of this new molecular mechanism.”

In this study, Constellation scientists showed rapid, potent and dose-dependent suppression of MYC gene expression using inhibitors of BET bromodomains, a family of proteins involved in regulating gene transcription. By inhibiting the binding of BET bromodomains to chromatin, researchers were able to suppress the transcription of selected genes involved in growth control, thereby blocking proliferation and inducing the death of cancer cells.

Researchers showed that reducing MYC transcript and protein levels resulted in extensive cell death in a variety of in vitro human leukemia and lymphoma cell lines. Exposing myeloma cell lines to a BET inhibitor resulted in significant inhibition of growth in 14 of the 15 cell lines. Constellation also demonstrated that treatment with a BET inhibitor resulted in significant anti-tumor activity in a xenograft mouse model of Burkitt’s lymphoma. Animals treated with a BET inhibitor showed significantly less bone marrow infiltration by lymphoma cells, without weight loss or other obvious adverse systemic effects. Researchers also found that a BET inhibitor exhibited significant anti-tumor activity in a xenograft mouse model of acute myeloid leukemia.  Mice treated with the BET inhibitor exhibited robust tumor growth inhibition (exceeding that seen with cytarabine, the standard of care) and even modest tumor regression.

Mark A. Goldsmith, M.D., Ph.D., president and chief executive officer of Constellation Pharmaceuticals, commented, “The development of small molecule BET bromodomain inhibitors represents a significant step forward in epigenetic-based drug discovery, and one that we are progressing toward the clinic. These findings suggest that our inhibitors will behave as selective therapies given their ability to target specific regulatory pathways, and that they may have broad utility as anti-cancer agents. The imperative for us now is to advance to the clinic with our structurally diverse set of BET inhibitors having the pharmacologic and pharmaceutical properties that will make them best-in-class treatments for patients. This program validates the power of our broad product engine, which leverages our deep expertise in chromatin biology and is applicable broadly across target classes.”

About Constellation Pharmaceuticals
Constellation Pharmaceuticals leverages insights from the rapidly expanding field of epigenetics
to discover and develop small molecule therapeutics for the treatment of cancer,
inflammatory/immunologic disorders and other diseases. Research at Constellation and by others
has shown that abnormal epigenetic regulation of gene expression contributes to many different
diseases. The company’s innovative product discovery engine targets both the enzymes that
modify the dynamic structure of chromatin and other proteins that interact with chromatin to
control gene expression. Restoration of normal gene expression through chromatin modulation
by highly selective and specific inhibitors promises to be a powerful avenue for the development
of important new medicines against a broad range of diseases. For more information, please visit
the company's website at www.constellationpharma.com.

About Constellation Pharmaceuticals
Constellation Pharmaceuticals leverages insights from the rapidly expanding field of epigenetics
to discover and develop small molecule therapeutics for the treatment of cancer,
inflammatory/immunologic disorders and other diseases. Research at Constellation and by others
has shown that abnormal epigenetic regulation of gene expression contributes to many different
diseases. The company’s innovative product discovery engine targets both the enzymes that
modify the dynamic structure of chromatin and other proteins that interact with chromatin to
control gene expression. Restoration of normal gene expression through chromatin modulation
by highly selective and specific inhibitors promises to be a powerful avenue for the development
of important new medicines against a broad range of diseases. For more information, please visit
the company's website at www.constellationpharma.com.

CAMBRIDGE, Mass. – February 1, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced the expansion of its leadership team with the appointment of Michael Cooper, M.D., as Chief Medical Officer and of Steven Paul, M.D., to the Board of Directors. Dr. Cooper was most recently Clinical Head of Oncology Translational Medicine at the Novartis Institutes for Biomedical Research, where his group contributed to the preclinical and clinical development of the Novartis oncology drug pipeline. Dr. Paul is Director of the Helen and Robert Appel Institute for Alzheimer's Research at Weill Cornell Medical College and is the former President of Lilly Research Laboratories.

"The appointment of these two seasoned drug development executives reflects the evolution of Constellation's R&D portfolio and the progress of our product pipeline," said Mark A. Goldsmith, M.D., Ph.D., President and Chief Executive Officer of Constellation. "Mike and Steve bring deep experience in drug development with track records of success, and they will help us take innovative therapies based on epigenetic regulation from the bench to patients."

Michael Cooper, M.D., Appointed Chief Medical Officer

Cooper's academic and pharmaceutical careers have been focused on the translation of novel cancer targets to new therapies, and he has broad expertise in cancer pharmacology, pharmacokinetics, biomarker development, and clinical trials. Cooper has contributed to the development of numerous first-in-class anti-cancer agents, including VELCADE® (bortezumib) and ERBITUX® (cetuximab).

Prior to Novartis, Cooper served as Vice President of Oncology Clinical Research at Millennium Pharmaceuticals, Inc., following a career in Oncology Clinical Design and Evaluation at Bristol-Myers Squibb. He has had numerous academic appointments, including Director of the Experimental Therapeutics Program in the Division of Medical Oncology at Duke University, and has served as a Senior Clinical Investigator in the Clinical Pharmacology and Medicine Branches of the National Cancer Institute. Cooper completed his Residency in Internal Medicine and Fellowship in Hematology/Oncology at Duke University Medical Center after receiving his M.D. from Duke University School of Medicine.

"Constellation is at the forefront in identifying the critical role that epigenetic targets and chromatin modulation play in disease," said Cooper. "I am delighted to have this opportunity to join the team as we continue to translate this novel science into new drug candidates."

Steven Paul, M.D., Elected to the Board of Directors

Paul had a distinguished 17-year tenure at Eli Lilly and Company where he held several key leadership roles, including President of Lilly Research Laboratories where he was responsible for the pharmaceutical research and development portfolio for Eli Lilly. Under his leadership, Lilly's research and development pipeline expanded to include approximately 70 new molecular entities across diverse therapeutic areas.

Prior to Lilly, Paul served as Scientific Director of the National Institute of Mental Health after a highly productive academic career that earned him numerous scientific awards and honors, including election to the Institute of Medicine of the National Academy of Sciences.

Dr. Paul joins Constellation's current Board of Directors, which includes Mark Levin, Partner, Third Rock Ventures; David Goeddel, Ph.D., Partner, The Column Group; Anthony Evnin, Ph.D., Partner, Venrock; Tom Maniatis, Ph.D., Isidore S. Edelman Professor and Chairman, Department of Biochemistry and Molecular Biophysics, Columbia University; Bob Tepper, M.D., Partner, Third Rock Ventures; and Mark A. Goldsmith, M.D., Ph.D., President and CEO, Constellation Pharmaceuticals.

About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a leading biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of epigenetics, a growing field of science that focuses on chromatin modifiers and the regulation of gene expression. The Company's academic founders are thought leaders in epigenetics responsible for numerous seminal advances. Constellation Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.constellationpharma.com.

VELCADE® is a registered trademark of Millennium Pharmaceuticals, Inc. ERBITUX® is a registered trademark of ImClone LLC.

Contact:
Barbara Yates
The Yates Network
Tel: 781-258-6153

NORWALK, Conn. – January 6, 2011 – The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, Inc. Since the inception of this MMRF program in 2006, $11 million has been committed to 11 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

The MMRF Biotech Investment Awards program has already seen impressive results with several new drugs advancing into clinical trials for patients including Astex’s AT7519 and Intellikine’s INK128 which are being studied through the Multiple Myeloma Research Consortium (MMRC), the MMRF’s sister organization.

"Despite the amazing progress of the last decade, there remains a critical need for more effective treatments and new approaches to treat multiple myeloma as the survival rate for multiple myeloma remains one of the lowest of any cancer. These 2010 awards support our commitment to the next-generation of therapeutics for patients," said Louise

M. Perkins, Ph.D., Chief Scientific Officer of the MMRF.

The 2010 MMRF Biotech Investment Awards support funding for two companies involved in the emerging area of epigenetic-based drug development, Constellation and Epizyme. The critical importance of epigenetic targets in both the development and potential treatment of multiple myeloma has become increasingly clear in recent years. In addition, Karyopharm is developing drugs that target crucial machinery of the cell involved in the nuclear import and export of key tumor suppressor and growth regulatory proteins in the cell, activating the body’s own systems for eliminating tumor cells.

"Constellation is committed to developing novel inhibitors of several epigenetic targets that play a role in multiple myeloma, and we are delighted to be working with the MMRF as we progress our compounds toward the clinic with the goal of providing new, safe and efficacious drugs to multiple myeloma patients,” said Mark A. Goldsmith, M.D., Ph.D., President and Chief Executive Officer of Constellation.

"This award from the MMRF provides Epizyme with another important source of funding to continue to advance the development of personalized therapies for patients with genetically defined cancers, including multiple myeloma," commented Robert J. Gould, Ph.D., President and Chief Executive Officer of Epizyme.

“The MMRF’s commitment to supporting Karyopharm will make a tremendous difference in advancing our innovative drugs towards clinical trials and in building continued hope for patients,” said Michael G. Kauffman, M.D., Ph.D., Chief Executive Officer of Karyopharm.

About the Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy’s diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world’s number-one private funder of multiple myeloma research, the MMRF has raised over $150 million since its inception to fund nearly 120 laboratories worldwide, including 60 new compounds and approaches in clinical trials and pre-clinical studies and has activated 30 clinical trials through its affiliate organization, the Multiple Myeloma Research Consortium (MMRC). As exceptional stewards of its donor’s investments, the MMRF consistently surpasses its peers in fiscal responsibility. For more information about the MMRF, please visit www.multiplemyeloma.org.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a leading biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of epigenetics, a new field of science that focuses on chromatin modifiers and the regulation of gene expression. The Company’s academic founders are thought leaders in epigenetics responsible for numerous seminal advances. Constellation Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company’s website at www.constellationpharma.com.

About Epizyme

Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors, a new class of targeted therapeutics for the treatment of genetically-defined cancer patients based on breakthroughs in the field of epigenetics. Genetic alterations in the HMTs are strongly associated with the underlying causes of multiple human diseases, including cancer. Epizyme’s hypothesis-driven approach represents the future of personalized therapeutics by creating better medicines for the right patients more quickly and at lower cost than traditional approaches.

www.epizyme.com

About Karyopharm

Karyopharm is a privately held oncology company headquartered in Natick, Massachusetts, focused on the development of modulators of nuclear transport as novel therapies for cancer, inflammatory and other diseases. Drs. Sharon Shacham, Michael Kauffman, Ronald DePinho, and Giulio Draetta founded the company in 2009. The nuclear transport machinery plays an integral role in the regulation of many molecules involved in a broad spectrum of human and animal disease, and drug discovery has been enhanced with the recent determination of the 3-dimensional structure of the nuclear pore complex. Karyopharm is developing novel selective inhibitors of nuclear export (SINE) for the treatment of cancer, autoimmune diseases and HIV. These SINEs act by forcing the nuclear localization of key tumor suppressor and growth regulatory proteins causing the selective death of cancer cells while sparing normal cells. The Karyopharm platform, utilizing rapid chemical optimization with integrated computational/in silico rational drug design, has yielded multiple novel active small molecule SINEs, which have shown potent activity in animal models of cancer. Additional programs focused on other aspects of nuclear export, as well as nuclear import, have been initiated.

Contacts

For MMRF

Terri Clevenger, 203-227-0209

tclevenger@continuumhealthcom.com

For Karyopharm

Michael Kauffman

mkauffman@karyopharm.com

For Epizyme

Robert Gould

rgould@epizyme.com

For Constellation

Jigar Raythatha

jigar.raythatha@constellationpharma.com

CAMBRIDGE, MA – January 4, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced the appointment of Dr. James E. Audia as Chief Scientific Officer. Audia joins Constellation following a highly productive career in drug discovery at Eli Lilly and Company.

Audia held several key leadership roles during his 23-year tenure at Lilly. As a Distinguished Lilly Scholar, the highest level of the company’s scientific ladder, Audia made seminal technical and strategic contributions to the Lilly drug pipeline. Prior to this role, Audia was Executive Director, Discovery Chemistry Research and Technologies, where he had global responsibility for delivery of small molecule drug candidates across all therapeutic areas. Audia also played a major role in companywide leadership of product strategy and portfolio management for Lilly for more than a decade. Over the course of his career, Audia’s scientific work has contributed to more than 12 development candidates, including transformative contributions to the treatment of Alzheimer’s disease through his discovery of both the first gamma secretase inhibitor and an industry-leading beta secretase inhibitor.

"We are delighted to have Jim join our leadership team at Constellation,” said Mark A. Goldsmith, M.D., Ph.D., President and Chief Executive Officer of Constellation. “He is widely recognized as an industry leader across all aspects of drug discovery and early development, and he brings a deep set of experiences and talents to Constellation at a time of great progress and promise for our lead compounds as they move toward the clinic.”

“Constellation is leading the field in the discovery and development of novel drugs against multiple classes of chromatin regulators implicated in critical therapeutic disease areas such as oncology and inflammation,” said Audia. “I am very pleased to have the opportunity to join this great team in the pursuit of drugs that will have a significant impact for patients.”

Audia is a named inventor on more than 90 issued US patents and has published and presented extensively. Audia received his Ph.D. in Organic Chemistry from the University of South Carolina, and did postdoctoral training at Yale University before joining Lilly.

Constellation also announced that Edward E. Harlow, Jr., Ph.D. has become Constellation Research Fellow, providing continued guidance in the area of cancer biology. Dr. Harlow was recently named Special Assistant to the Director at the National Cancer Institute, and will be working with the Institute on several strategic initiatives in cancer research.

About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a leading biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of epigenetics, a new field of science that focuses on chromatin modifiers and the regulation of gene expression. The Company’s academic founders are thought leaders in epigenetics responsible for numerous seminal advances. Constellation Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company’s website at www.constellationpharma.com.

Click the image to watch the full episode

CAMBRIDGE, Mass. – June 2, 2010 – Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced that it has raised $22 million in a Series B financing round. The financing round was led by SR One, the independent corporate healthcare venture capital arm of GlaxoSmithKline, with participation from existing investors Third Rock Ventures, The Column Group, Venrock, and Altitude Life Science Ventures. This Series B financing brings the total amount of capital raised by Constellation in the two years since its founding to $54 million.

Proceeds from the financing will be used to advance the development of Constellation’s pipeline of compounds towards the clinic. These funds will also enable Constellation to continue applying its innovative epigenetics product engine to probe multiple classes of novel drug targets involved in chromatin regulation and disease.

"We are delighted to have SR One, a premier venture capital investor, lead the Series B round. Their investment highlights the value created since our Series A financing round and the transformative potential of epigenetics as a platform for novel therapeutics" said Mark A. Goldsmith, M.D., Ph.D., President and Chief Executive Officer of Constellation Pharmaceuticals. "Our differentiated ability to develop a pipeline of drugs against a broad range of epigenetic target classes is a core feature of our business strategy, and this investment allows us to accelerate our efforts to bring these discoveries to the patient."

About Constellation Pharmaceuticals
Constellation Pharmaceuticals is the leading biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of epigenetics, a new field of science that focuses on selective regulators of gene function and expression. The Company’s academic founders represent the core thought leaders in epigenetics and are responsible for numerous key advances in the field. Constellation Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.constellationpharma.com.

Constellation’s Board of Directors include: Mark Levin, Partner, Third Rock Ventures; David Goeddel, Ph.D., Partner, The Column Group; Anthony Evnin, Ph.D., Partner, Venrock; Tom Maniatis, Ph.D., Isidore S. Edelman Professor and Chairman, Department of Biochemistry and Molecular Biophysics, Columbia University; Bob Tepper, M.D., Partner, Third Rock Ventures; and Mark A. Goldsmith, M.D., Ph.D., President and CEO, Constellation Pharmaceuticals.

About Epigenetics
Epigenetics is an exciting new field of biology that involves the study of chemical modifications of both DNA and of its packaging proteins ("chromatin"), which are collectively called the ‘epigenome’. The genome, or DNA, is the "blueprint" for the human body, consisting of thousands of genes, which are the fundamental units of information necessary for normal cell growth and development. The epigenome plays an important role in regulating the expression of genes, that is, switching genes on or off – or in the case of disease, for switching genes on or off incorrectly. This new field of epigenetic science provides the opportunity to create a broad new class of human therapeutics targeting enzymes that chemically modify DNA or chromatin and therefore influence gene expression.

Contact:
Kathryn Morris
The Yates Network
Tel: 845-635-9828

CAMBRIDGE, MA – January 20, 2010 – Constellation Pharmaceuticals, Inc. today announced that it has appointed Garen Bohlin as the company's Executive Vice President. Mr. Bohlin will be responsible for Constellation's corporate operations and finance function.

Mr. Bohlin has held senior executive posts in leading biotechnology companies for the past 25 years. Most recently he served as Chief Operating Officer of Sirtris Pharmaceuticals, where he played key roles in the general management of Sirtris, as well as in its initial public offering, the sale of the company to GlaxoSmithKline for over $700 million, and the post-acquisition integration. Prior to his role at Sirtris, Mr. Bohlin was the founding Chief Executive Officer of Syntonix Pharmaceuticals where he positioned the company for its eventual sale to Biogen Idec. He began his career in the biotechnology sector at Genetics Institute, where he held multiple executive positions culminating with responsibility for most of the non-scientific areas in this fully integrated biopharmaceutical company. He also played an integral role in structuring the sale of Genetics Institute to American Home Products (Wyeth) at an implied valuation of approximately $3 billion. Mr. Bohlin was a partner at Arthur Andersen & Co. before assuming various operating roles in the life sciences field.

"We are delighted and proud that Garen is bringing his operational talents to Constellation," said Mark A. Goldsmith, M.D., Ph.D., Chief Executive Officer of Constellation Pharmaceuticals. "Garen is widely respected for his impressive record of delivering strong investor returns from innovative companies. He has helped steer drug discovery companies through all stages of their life cycle and will be an enormous organizational asset as we deploy our product engine to bring new therapeutics forward on behalf of patients."

"Constellation is a clear leader in the cutting edge field of epigenetics," said Mr. Bohlin. "The company has amassed an impressive group of internal and external scientific experts in this field and is poised to lead the translation of this groundbreaking biology and discovery platform into drugs that will address challenging therapeutic disease areas such as cancer. I believe that the company is well positioned to create substantial value for its investors in the years ahead."

About Constellation Pharmaceuticals
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science that focuses on selective regulators of gene function and expression. Constellation's initial focus is in oncology, and the Company's platform will also be applicable to other therapeutic areas including autoimmune, inflammatory and neurological diseases. The Company's academic founders represent the core thought leaders in epigenetics responsible for key advances, insights and discoveries in the field. Constellation Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.constellationpharma.com.

Constellation's Board of Directors include: Anthony Evnin, Partner, Venrock; David Goeddel, Ph.D., Partner, The Column Group; Mark Levin, Partner, Third Rock Ventures; Tom Maniatis, Ph.D., Professor, Harvard University; Robert Tepper, M.D., Partner, Third Rock Ventures; and Mark A. Goldsmith, M.D., Ph.D., CEO, Constellation Pharmaceuticals. The Company's Chief Scientific Officer is Edward E. Harlow, Jr., Ph.D. and its Chief Business Officer is Kerry Reinertsen, Ph.D.

Constellation Pharmaceuticals was founded by three of the foremost authorities and leaders within the field of Epigenetics: Danny Reinberg, Ph.D, Professor of Biochemistry at the New York University School of Medicine and an Investigator of the Howard Hughes Institute; Yang Shi, Ph.D., Professor of Pathology at the Harvard Medical School and David Allis, Ph.D., Professor and Head of the Laboratory of Chromatin Biology at The Rockefeller University.

About Epigenetics
Epigenetics is an exciting new field of biology that involves chemical modifications of both DNA and of its packaging proteins ("chromatin"), which are collectively called the 'epigenome.' The genome, or DNA, is the "blueprint" for the human body, consisting of thousands of genes, which are the fundamental units of information necessary for normal cell growth and development. In contrast, the epigenome plays a critical role in regulating the expression of genes, that is, switching genes on or off – or in the case of disease, for switching genes on or off incorrectly. This new field of Epigenetic science provides the opportunity to create a broad new class of human therapeutics targeting selective regulators of epigenetic function.

Contact
Adriana Jenkins
The Yates Network
617-744-1713